Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure
Phosphodiesterase type 5 (PDE5) selectively hydrolyses the second messenger cGMP into 5′-GMP, thereby regulating its intracellular concentrations. Dysregulation of the cGMP-dependent pathway plays a significant role in various cardiovascular diseases. Therefore, its modulation by drugs, such as PDE5...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2018
|
| In: |
British journal of pharmacology
Year: 2017, Jahrgang: 175, Heft: 2, Pages: 223-231 |
| ISSN: | 1476-5381 |
| DOI: | 10.1111/bph.13749 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1111/bph.13749 Verlag, Volltext: https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1111/bph.13749 
|
| Verfasserangaben: | Sevil Korkmaz‐Icöz, Tamás Radovits, Gábor Szabó |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 158226970X | ||
| 003 | DE-627 | ||
| 005 | 20230427193159.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 181024r20182017xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bph.13749 |2 doi | |
| 035 | |a (DE-627)158226970X | ||
| 035 | |a (DE-576)51226970X | ||
| 035 | |a (DE-599)BSZ51226970X | ||
| 035 | |a (OCoLC)1341020479 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Korkmaz-İçöz, Sevil |e VerfasserIn |0 (DE-588)1062748697 |0 (DE-627)806830336 |0 (DE-576)420147845 |4 aut | |
| 245 | 1 | 0 | |a Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure |c Sevil Korkmaz‐Icöz, Tamás Radovits, Gábor Szabó |
| 264 | 1 | |c 2018 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a First published: 18 February 2017 | ||
| 500 | |a Gesehen am 24.10.2018 | ||
| 520 | |a Phosphodiesterase type 5 (PDE5) selectively hydrolyses the second messenger cGMP into 5′-GMP, thereby regulating its intracellular concentrations. Dysregulation of the cGMP-dependent pathway plays a significant role in various cardiovascular diseases. Therefore, its modulation by drugs, such as PDE5 inhibitors, may represent an effective therapeutic approach. There are currently four PDE5 inhibitors available for the treatment of erectile dysfunction: sildenafil, vardenafil, tadalafil and avanafil. Sildenafil and tadalafil have also received Food and Drug Administration approval for the treatment of pulmonary arterial hypertension. This review summarizes the pharmacological aspects and clinical potential of PDE5 inhibition for the treatment of myocardial ischaemia/reperfusion injury and heart failure. Linked Articles This article is part of a themed section on Inventing New Therapies Without Reinventing the Wheel: The Power of Drug Repurposing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.2/issuetoc | ||
| 534 | |c 2017 | ||
| 700 | 1 | |a Radovits, Tamás |e VerfasserIn |0 (DE-588)1081943203 |0 (DE-627)846898101 |0 (DE-576)454965869 |4 aut | |
| 700 | 1 | |a Szabó, Gábor |d 1969- |e VerfasserIn |0 (DE-588)1022955152 |0 (DE-627)717338681 |0 (DE-576)366215485 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of pharmacology |d Malden, MA : Wiley, 1946 |g 175(2018), 2, Seite 223-231 |h Online-Ressource |w (DE-627)324659016 |w (DE-600)2029728-2 |w (DE-576)094504113 |x 1476-5381 |7 nnas |a Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure |
| 773 | 1 | 8 | |g volume:175 |g year:2018 |g number:2 |g pages:223-231 |g extent:9 |a Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bph.13749 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1111/bph.13749 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20181024 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 1022955152 |a Szabó, Gábor |m 1022955152:Szabó, Gábor |d 910000 |d 910200 |e 910000PS1022955152 |e 910200PS1022955152 |k 0/910000/ |k 1/910000/910200/ |p 3 |y j | ||
| 998 | |g 1081943203 |a Radovits, Tamás |m 1081943203:Radovits, Tamás |d 910000 |d 910200 |e 910000PR1081943203 |e 910200PR1081943203 |k 0/910000/ |k 1/910000/910200/ |p 2 | ||
| 998 | |g 1062748697 |a Korkmaz-İçöz, Sevil |m 1062748697:Korkmaz-İçöz, Sevil |d 910000 |d 910200 |e 910000PK1062748697 |e 910200PK1062748697 |k 0/910000/ |k 1/910000/910200/ |p 1 |x j | ||
| 999 | |a KXP-PPN158226970X |e 3029653684 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"9 S."}],"recId":"158226970X","relHost":[{"disp":"Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failureBritish journal of pharmacology","physDesc":[{"extent":"Online-Ressource"}],"recId":"324659016","language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 06.02.13"],"title":[{"subtitle":"BJP online","title":"British journal of pharmacology","title_sort":"British journal of pharmacology"}],"origin":[{"publisher":"Wiley ; Macmillan ; Nature Publ. Group","publisherPlace":"Malden, MA ; Basingstoke ; Basingstoke","dateIssuedKey":"1946","dateIssuedDisp":"1946-"}],"id":{"zdb":["2029728-2"],"doi":["10.1111/(ISSN)1476-5381"],"issn":["1476-5381"],"eki":["324659016"]},"part":{"volume":"175","year":"2018","extent":"9","text":"175(2018), 2, Seite 223-231","issue":"2","pages":"223-231"},"name":{"displayForm":["The British Pharmacological Society"]},"pubHistory":["1.1946 -"],"titleAlt":[{"title":"BJP online"}]}],"person":[{"given":"Sevil","role":"aut","family":"Korkmaz-İçöz","display":"Korkmaz-İçöz, Sevil"},{"family":"Radovits","given":"Tamás","role":"aut","display":"Radovits, Tamás"},{"display":"Szabó, Gábor","family":"Szabó","role":"aut","given":"Gábor"}],"origin":[{"dateIssuedDisp":"2018","dateIssuedKey":"2018"}],"note":["First published: 18 February 2017","Gesehen am 24.10.2018"],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title":"Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure","title_sort":"Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure"}],"name":{"displayForm":["Sevil Korkmaz‐Icöz, Tamás Radovits, Gábor Szabó"]},"id":{"eki":["158226970X"],"doi":["10.1111/bph.13749"]}} | ||
| SRT | |a KORKMAZICOTARGETINGP2018 | ||